Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
EGLT's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. EGLT: No Debt )
EGLT' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: No Debt

Equity to Asset 0.82
EGLT's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. EGLT: 0.82 )
EGLT' s 10-Year Equity to Asset Range
Min: 0.82   Max: 0.85
Current: 0.82

0.82
0.85
Z-Score: 2.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA (%) -99.23
EGLT's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. EGLT: -99.23 )
EGLT' s 10-Year ROA (%) Range
Min: -307.77   Max: -96.51
Current: -99.23

-307.77
-96.51
ROC (Joel Greenblatt) (%) -469.01
EGLT's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. EGLT: -469.01 )
EGLT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -906.13   Max: -469.01
Current: -469.01

-906.13
-469.01
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

EGLT Guru Trades in

EGLT Guru Trades in

EGLT Guru Trades in

Q1 2014

EGLT Guru Trades in Q1 2014

Steven Cohen 31,594 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.70
EGLT's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. EGLT: 2.70 )
EGLT' s 10-Year P/B Range
Min: 2.42   Max: 4.44
Current: 2.7

2.42
4.44
Current Ratio 15.02
EGLT's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. EGLT: 15.02 )
EGLT' s 10-Year Current Ratio Range
Min: 0.59   Max: 29.19
Current: 15.02

0.59
29.19
Quick Ratio 15.02
EGLT's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. EGLT: 15.02 )
EGLT' s 10-Year Quick Ratio Range
Min: 0.59   Max: 29.19
Current: 15.02

0.59
29.19

Valuation & Return

vs
industry
vs
history

Business Description

Industry: »
Compare: » details
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
No related article found.


More From Other Websites
Nasdaq stocks posting largest percentage decreases Aug 26 2014
EGALET CORP Financials Aug 22 2014
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 18 2014
Egalet Announces Successful End-of-Phase 2 Meeting With the FDA for Egalet-002 Aug 18 2014
EGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 14 2014
EGALET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 12 2014
Egalet Reports Second Quarter 2014 Financial Results and Provides Business Update Aug 12 2014
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 06 2014
Egalet Announces Topline Results from Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001 Aug 06 2014
Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001 Aug 06 2014
Egalet to Present at the Canaccord Genuity Growth Conference on August 13 Jul 30 2014
Egalet to Present at the Canaccord Genuity Growth Conference on August 13 Jul 30 2014
Egalet to Host Conference Call and Webcast to Discuss Second Quarter Financial Results on August 12,... Jul 29 2014
Egalet to Host Conference Call and Webcast to Discuss Second Quarter Financial Results on August 12,... Jul 29 2014
EGALET CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jul 28 2014
Egalet Appoints Jeffrey M. Dayno, M.D. as Chief Medical Officer Jul 28 2014
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 15 2014
Egalet reports positive top-line results from Category 1 abuse deterrence study Jul 15 2014
Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating... Jul 15 2014
EGALET CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial... Jun 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK